Mirum Pharmaceuticals, Inc. 4

Mirum Pharmaceuticals CEO Christopher Peetz exercised 20,000 options at $2.936 and sold 20,000 Mirum (MIRM) common shares around $98.5–$100.1 on August 10, 2026 under a Rule 10b5-1 plan.

On August 10, 2026, Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised 20,000 stock options at an exercise price of $2.936 per share and simultaneously sold 20,000 shares of common stock in three open market transactions under a Rule 10b5-1 trading plan at weighted average prices of $98.51, $99.25, and $100.14, generating total sale proceeds of roughly $1.99 million and option exercise cost of about $0.06 million. After these transactions, Peetz directly owned 194,309 shares of Mirum common stock, with additional indirect ownership of 187,500 shares held by The Peetz Family Trust, and the exercised option is now fully vested and partially utilized.

Filing Facts

CIK

1759425

Ticker

MIRM

Form

4

Source Type

fda

Accession

0001614740-26-000012

Alert Tier

7